schemaVersion:
Form 1-K Issuer Information | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-K | OMB APPROVAL |
| OMB Number: 3235-0720 Estimated average burden hours per response: 600.0 |
1-K: Filer Information
Issuer CIK | 0001700800 |
Issuer CCC | XXXXXXXX |
Is filer a shell company? | Yes No |
Is the electronic copy of an official filing submitted in paper format? | |
File Number | |
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? | Yes No |
Successor File Number |
Is this a LIVE or TEST Filing? | LIVE TEST |
Would you like a Return Copy? | |
Period | 12-31-2017 |
Name | |
Phone | |
E-Mail Address |
Notify via Filing Website only? |
1-K: Tab 1 Notification
This Form 1-K is to provide an | Annual Report Special Financial Report for the fiscal year |
Fiscal Year End | 12-31-2017 |
Exact name of issuer as specified in the issuer's charter | EMERALD HEALTH PHARMACEUTICALS INC. |
CIK | 0001700800 |
Jurisdiction of Incorporation / Organization | DELAWARE |
I.R.S. Employer Identification Number | 82-0669961 |
Address 1 | 5910 PACIFIC CENTER BLVD. |
Address 2 | SUITE 300 |
City | SAN DIEGO |
State/Country | CALIFORNIA |
Mailing Zip/ Postal Code | 92121 |
Phone | 858-352-0622 |
Title of each class of securities issued pursuant to Regulation A | Common Stock |
1-K: Summary Information Regarding Prior Offering and Proceeds
Summary Information
The following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.
Commission File Number of the offering statement | 024-10810 |
Date of qualification of the offering statement | 03-29-2018 |
Date of commencement of the offering | 03-29-2018 |
Amount of securities qualified to be sold in the offering | 10000000 |
Amount of securities sold in the offering | 0 |
Price per security | $ 5.0000 |
The portion of aggregate sales attributable to securities sold on behalf of the issuer | $ 50000000.00 |
The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders | $ 0.00 |
Fees in connection with this offering and names of service providers.
Underwriters - Name of Service Provider | N/A | Underwriters - Fees | $ 0.00 |
Sales Commissions - Name of Service Provider | N/A | Sales Commissions - Fee | $ 0.00 |
Finders' Fees - Name of Service Provider | N/A | Finders' Fees - Fees | $ 0.00 |
Accounting or Audit - Name of Service Provider | Deloitte & Touche LLP | Accounting or Audit - Fees | $ 55000.00 |
Legal - Name of Service Provider | Morrison & Foerster LLP | Legal - Fees | $ 135000.00 |
Promoters - Name of Service Provider | N/A | Promoters - Fees | $ 0.00 |
Blue Sky Compliance - Name of Service Provider | N/A | Blue Sky Compliance - Fees | $ 0.00 |
CRD Number of any broker or dealer listed | |
Net proceeds to the issuer | $ 49750000.00 |
Clarification of responses (if necessary) | The expected fees in connection with this offering total $250,000. The expected fees include the $190,000 listed above as well as an additional $60,000 for other associated fees. |